ust because you’ve been made redundant, you shouldn’t have to give up your daily dose of endorphins. In fact, that living room HIIT class has never been more needed for those who’ve lost their jobs or homes from the fallout of Covid-19.
Thankfully, London’s top fitness heroes have come to the rescue, offering free workouts for frontline workers, job seekers and struggling artists amid lockdown 2.0.
From BLOK gym’s complimentary online membership for out-of-work creatives to Frame’s free hero hotline, these are the studios offering free fitness support for those who need it most.
BLOK fitness subscription
The platform offers more than 170 on-demand video classes, from yoga to HIIT to boxing to dance, with new content released every week. Each week, there are also 60 live classes.
Co-Founder and CEO of BLOK, Ed Stanbury says: “BLOKtv is more than just a temporary solution to lockdown – it’s an online community for creative thinkers who want to maintain a healthy mind and body. Community has always been at the heart of BLOK, and it’s our aim to provide a platform which both our instructors and creative communities can really feel part of.
“As we continue through the second lockdown, it feels like now more than ever we need to keep our community moving. We believe that fitness fuels creativity, allowing people to learn new skills, build strength, flexibility, and ultimately have fun. BLOK is not just about getting fitter, it should make you feel better in every part of your life.”
To keep the nation fit during these cold days and dark evenings, leading gym chain PureGym has made its previously paid-for workout app – normally £19.99 a month – free for everyone throughout lockdown 2.0.
It features over 400 different workouts of various levels, classes and advice to help anyone maintain both physical and mental health during this second lockdown. Just download the PureGym app from the Apple App Store or Google Play to get started.
Stephen Rowe, Chief Marketing Officer of PureGym, says: “As the days shorten and the weather turns, exercising outdoors isn’t feasible for the majority of people. Therefore, we have made the decision to make the PureGym app and the hundreds of workouts available on the platform free, to help as many people as we can, whether you go to PureGym, to another gym or no gym at all, this app is now for everyone and we hope it’ll help people to keep fit throughout November and beyond”.
Adults who participate in daily physical activity are 20 to 30 per cent less likely to experience depression so fizzy fitness chain Frame has introduced a hero hotline to offer its daily dose of endorphins for
GENEVA (Reuters) – The world is now at a critical juncture in the COVID-19 pandemic and some countries are on a dangerous path, facing the prospect of health services collapsing under the strain, the head of the World Health Organization said on Friday.
“We are at a critical juncture in the COVID-19 pandemic, particularly in the Northern hemisphere,” WHO Director-General Tedros Adhanom Ghebreyesus told a news conference. “The next few months are going to be very tough and some countries are on a dangerous track.”
“We urge leaders to take immediate action, to prevent further unnecessary deaths, essential health services from collapsing and schools shutting again. As I said it in February and I’m repeating it today: This is not a drill.”
Tedros said too many countries were now seeing an exponential increase in infections, “and that is now leading to hospitals and intensive care units running close or above capacity — and we’re still only in October”.
He said countries should take action to limit the spread of the virus quickly. Improving testing, tracing of contacts of those infected and isolation of those at risk of spreading the virus would enable countries to avoid mandatory lockdowns.
(Writing by Peter Graff; Editing by Kevin Liffey)
Copyright 2020 Thomson Reuters.
The CDC on Wednesday ramped up its criteria for who’s at risk of contracting the coronavirus, in a move with major implications for school and workplace reopenings.
The updated guidance defines a “close contact” as anyone who spends at least 15 minutes within six feet of an infected individual over a 24-hour period. The agency previously applied that designation to people who spent 15 consecutive minutes within six feet of someone with Covid-19.
“Individuals who had a series of shorter contacts but over time added up to more than 15 minutes became infected,” CDC Director Robert Redfield said at a briefing, citing a study of multiple non-consecutive exposures. Redfield was joined by HHS Secretary Alex Azar and Jay Butler, the CDC’s deputy director for infectious diseases, who warned that the U.S. is showing a “distressing trend” with cases surging over 75 percent of the country.
The details: The guidance is based on a study out today showing brief exposures to infected individuals and resulted in virus spread. The study involved a Vermont correctional facility employee who tested positive after short interactions with multiple inmates who were infected.
The study said the correctional officer was never with the inmates for 15 consecutive minutes. The Vermont Department of Health said the officer wore a cloth mask, gown and goggles and had 22 interactions totaling about 17 minutes with six unmasked inmates who tested positive for the virus.
What’s next: The updated guidance could change how public health departments across the country conduct their contact tracing, by increasing the pool of potentially infected individuals. It also could upend plans to reopen schools and businesses that had been based around the earlier guidance, as President Donald Trump continues to call for a return to pre-pandemic conditions. The CDC in May released guidelines for reopening schools that Trump later disavowed, saying they were too burdensome.
The U.S. is reporting an average 60,000 cases per day with the Midwest seeing the largest increases in cases. Officials warned conditions could get worse as the cold weather sends people indoors, where the virus can spread more rapidly.
So far, there have been 8.3 million reported cases in the U.S. and more than 221,000 deaths.
The EU’s medicines regulator has requested the complete results of the World Health Organization’s remdesivir trial, the European Commission said, after the study found the Covid-19 treatment to have no substantial effect on rates of survival.
The European Commission announced last week that it had signed a deal with the developer, Gilead Sciences, to supply 500,000 treatment courses of the drug, worth more than €1bn. Trial data had shown the treatment cut the time to recover from Covid-19 by as much five days, while Gilead had said the drug may also reduce the likelihood of death.
But the results from the WHO’s highly anticipated Solidarity trial, first reported by the Financial Times, found that remdesivir and other three other potential drug regimens “appeared to have little or no effect on 28-day mortality or the in-hospital course of Covid-19 among hospitalised patients”.
According to WHO officials, the organisation told Gilead of the findings of the Solidarity trial in September, as long as two weeks before the European Commission announced its deal to procure the drug.
“[The WHO] made a presentation to Gilead and other companies [on the results of the trial] on September 23,” Ana Maria Henao-Restrepo, a medical officer at the WHO, said at a briefing on Friday. “On the following Monday, September 28, [the WHO] forwarded [to Gilead] not only the graph, figures and tables, but the first draft of the manuscript”.
Ms Henao-Restrepo said the manuscript was “not exactly” the same as the one published late on Thursday, but that it contained the same numbers and conclusions.
Richard Peto, emeritus professor of medical statistics and epidemiology at Oxford university and chief statistician on the Solidarity trial, said the preliminary results “came to the same conclusions that you now see”.
In response to a request for comment, Gilead said the initial manuscript it had received from the WHO in September had been “heavily redacted”.
“As of today, Gilead has still not received the underlying data sets or statistical analysis plan necessary to validate the results,” it said. “We received the full manuscript, which included materially different information than what was included in the initial draft, only hours before it was published yesterday.”
The European Commission told the FT it had not made any payments under the October 8 Gilead agreement, which gives 36 European countries, including the UK, the option to buy future remdesivir supplies.
“[European Medicines Agency] will look at the Solidarity data . . . to see if any changes are needed to the way these medicines are used,” it said.
Gilead has priced remdesivir at $2,340 per five-day course on the basis that it cuts the cost of care by reducing the length of hospital stays, though the Solidarity results may have damaged that thesis.
Yannis Natsis, a policy manager at the European Public Health Alliance and a board member at the EMA, said the situation with remdesivir felt like “déjà-vu”, citing the large sums of money spent on past antivirals, such as Tamiflu, only